GSK2837808A
CAS No. 1445879-21-9
GSK2837808A ( —— )
产品货号. M22182 CAS No. 1445879-21-9
GSK2837808A 是一种有效的选择性乳酸脱氢酶 A (LDHA) 抑制剂(LDHA 和 LDHB 的 IC50 值分别为 1.9 和 14 nM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥996 | 有现货 |
|
| 10MG | ¥1596 | 有现货 |
|
| 25MG | ¥2908 | 有现货 |
|
| 50MG | ¥3896 | 有现货 |
|
| 100MG | ¥5654 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称GSK2837808A
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述GSK2837808A 是一种有效的选择性乳酸脱氢酶 A (LDHA) 抑制剂(LDHA 和 LDHB 的 IC50 值分别为 1.9 和 14 nM)。
-
产品描述GSK2837808A is a potent and selective inhibitor of lactate dehydrogenase A (LDHA) (IC50s: 1.9 and 14 nM for LDHA and LDHB, respectively). GSK2837808A inhibits lactate production in hypoxia but at higher concentrations than in normoxia (EC50=10 μM). It also reduces ECAR (EC50=10 μM). LDH inhibition by GSK2837808A alters multiple metabolic pathways in Snu398 cells. GSK2837808A rapidly and profoundly inhibits lactate production rates in multiple cancer cell lines including hepatocellular and breast carcinomas. GSK2837808A potency does not correlate with LDHA, LDHB, or the total LDH expression levels. The potency of GSK2837808A across 30 cancer cell lines with different LDHA and LDHB expression levels range from 400 nM to no effect (EC50 reported as 30 μM).GSK2837808A (p.o.; 50 mg/kg in rats; 100 mg/kg in mice) treatment, causes blood compound levels at or below the detection limit of 2.5 ng/mL. Clearance following IV infusion of GSK2837808A at 0.25 mg/kg is displayed to be 69 mL/minute/kg in rats and it exceeds the animal liver blood flow.
-
体外实验GSK2837808A rapidly and profoundly inhibits lactate production rates in multiple cancer cell lines including hepatocellular and breast carcinomas. The potency of GSK2837808A across 30 cancer cell lines with different LDHA and LDHB expression levels ranges from 400 nM to no effect (EC50 reported as 30 μM). GSK2837808A potency does not correlate with LDHA, LDHB, or the total LDH expression levels. GSK2837808A inhibits lactate production in hypoxia but at higher concentrations than in normoxia (EC50=10 μM). It also reduces ECAR with EC50=10 μM. LDH inhibition by GSK2837808A alters multiple metabolic pathways in Snu398 cells.
-
体内实验Clearance following IV infusion of GSK2837808A at 0.25 mg/kg is shown to be 69 mL/minute/kg in rats, which exceeds the animal liver blood flow. Oral dosing of GSK2837808A at 50 mg/kg in rats or 100 mg/kg in mice results in blood compound levels at or below the detection limit of 2.5 ng/mL.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Dehydrogenase
-
受体LDHA|LDHB
-
研究领域——
-
适应症——
化学信息
-
CAS Number1445879-21-9
-
分子量649.62
-
分子式C31H25F2N5O7S
-
纯度>98% (HPLC)
-
溶解度DMSO:95 mg/mL (146.24 mM)
-
SMILESCOc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Billiard J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013 Sep 6;1(1):19.
产品手册
关联产品
-
CAY10566
CAY10566 在阻断 HepG2 细胞中饱和长链脂肪酸-CoA (LCFA-CoAs) 转化为单不饱和 LCFA-CoA 方面表现出优异的细胞活性(IC50=7.9 nM 或 6.8 nM)。 CAY10566 是一种有效的、口服生物可利用的、选择性硬脂酰辅酶A去饱和酶1 (SCD1) 抑制剂,在小鼠和人类酶测定中,IC50 分别为 4.5 和 26 nM。
-
CP-642931
Sorbitol dehydrogenase-IN-1 是一种有效的具有口服活性的山梨醇脱氢酶 sorbitol dehydrogenase 抑制剂,对大鼠和人类的 IC50 s 值分别为 4、5 nM。
-
ASLAN003
ASLAN003 是一种口服有效的 DHODH(人二氢乳清酸脱氢酶)抑制剂,具有抗肿瘤活性。
021-51111890
购物车()
sales@molnova.cn

